



EDCTP Stakeholder Meeting on Neglected Infectious Diseases

27-28 June 2013
 Ministry of Foreign Affairs
 Bezuidenhoutseweg 67, The Hague, the Netherlands

Thursday 27 June 2013

09:30-10:30	Registration (Security check & badge collection)
10:00-10:30	Coffee/Tea
10.30-10:45	Opening addresses <i>Professor Hannah Akuffo, Chair of the EDCTP General Assembly and member for Sweden</i> <i>Professor Charles Mgone, EDCTP Executive Director</i>
10:45-11:00	Introduction by Chairpersons <i>Professor John Gyapong, University of Ghana</i> <i>Professor Alison Elliott, London School of Hygiene & Tropical Medicine</i>
11:00-11:55	Keynote address <i>Professor Achim Hoerauf, Institute of Medical Microbiology, Immunology & Parasitology, University Hospital Bonn</i>
11:55-12:15	Plans and Progress towards EDCTP2 <i>Dr Michael Makanga, EDCTP Director South-South Cooperation and Head of Africa Office</i>
12:15-13:00	Lunch
13:00-13:15	Diagnostics <i>Introduction: Professor Joseph Ndung'u, Foundation for Innovative New Diagnostics</i>
13:15-15:00	Diagnostics <i>Discussion and recommendations</i>
15:00-15:15	Coffee/Tea
15:15-15:30	Vaccines <i>Introduction: Dr Odile Leroy, European Vaccine Initiative</i>
15:30-17:15	Vaccines <i>Discussion and recommendations</i>
17:15-17:30	Closing remarks, Day 1 <i>Chairpersons</i>
17:45	Drinks reception hosted by the Ministry of Foreign Affairs, The Netherlands

Friday 28 June 2013

09:00-09:25	Registration (Security check & badge collection)
09:00-09:20	Coffee/Tea
09:20-09:30	Introduction <i>Mrs Marja Esveld, EDCTP General Assembly member for The Netherlands</i>
09:30-09:45	Treatment <i>Introduction: Dr Nathalie Strub Wourgaft, Drugs for Neglected Diseases Initiative</i>
09:45-11:15	Treatment <i>Discussion and recommendations</i>
11:15-11:30	Coffee/tea
11:30-13:00	Partnerships and collaborations



Panel Discussion:

Dr Ole Olesen, European Commission

Dr Jutta Reinhard-Rupp, Merck Serono

Mrs Martina Gliber, Fondation Mérieux

Dr Christian Loucq, International Vaccine Institute

Dr Morven Roberts, UK Medical Research Council

Dr John Reeder, WHO TDR

13:00-13:15	Panel summary and recommendations
13:15-14:00	Lunch
14:00-15:45	Capacity building <i>Discussion and recommendations</i>
15:45-16:00	Coffee/Tea
16:00-17:00	Summary and recap of recommendations
17:00-17:15	Closing remarks <i>Professor Charles Mgone, EDCTP Executive Director</i>



Speaker Biographies

Chairpersons

Professor John Gyapong
University of Ghana

Professor Gyapong is the Pro-Vice Chancellor for Research Innovation and Development of the University of Ghana. He is a Public Health Physician and an Epidemiologist. He studied Medicine in Ghana and Public Health (MSc) and Epidemiology (PhD) at the London School of Hygiene and Tropical Medicine of the University of London. His main area of research is infectious disease epidemiology, especially lymphatic filariasis and other neglected tropical diseases. For 12 years he was Director for Research and Development of the Ghana Health Service and was also responsible for Ghana Filariasis Elimination and Onchocerciasis Control Programmes. Before assuming responsibility as Pro-Vice Chancellor he was the Vice-Dean and Professor in Epidemiology and Disease Control at the School of Public Health of the University of Ghana. He has over 100 publications in peer reviewed journals.

Professor Alison Elliott
MRC/UVRI Uganda Research Unit on AIDS; London School of Hygiene & Tropical Medicine (LSHTM)

Alison Elliott is Professor of Tropical Epidemiology at the London School of Hygiene and Tropical Medicine (LSHTM). She is based in Uganda where she holds the post of Head of the Co-infection Studies Programme at the UK Medical Research Council/Uganda Virus Research Institute (UVRI). Her interests in tropical medicine developed during her medical training in the UK, as part of which she undertook an elective with the MRC-Gambia. After medical training she joined LSHTM as a research fellow and from 1988 to 1992 she carried out research on the interaction between tuberculosis and HIV infection in Zambia. Following an Infectious Diseases Fellowship in Colorado which provided an opportunity to learn about management of MDR-TB and to extend her expertise in basic immunology, Professor Elliott has been based in Uganda at UVRI since 1997. Her current research focuses on interactions between co-infections, the effects of helminth infection on immune responses to vaccines and on infectious and allergic disease incidence in Uganda. She is current holder of a Wellcome Trust Senior Fellowship and co-PI of several major grants that support research and capacity building in Uganda and across East Africa.

Plenary Speaker

Professor Doctor Achim Hoerauf
Institute of Medical Microbiology, Immunology & Parasitology, University Hospital Bonn

Professor Hoerauf is Director of the Institute of Medical Microbiology, Immunology & Parasitology at the University Hospital Bonn. Following medical training at the University of Erlangen, he began his research career in 1990, holding positions as Director of Helminthology at the Bernhard-Nocht-Institut, Director of the Institute of Medical Parasitology at the Rheinische Friedrich-Wilhelms-University Bonn before taking up his current post in 2005 as Institute Director at the University Hospital Bonn. His research interests include T cell modulated immunosuppression during chronic worm infections and its genetic basis, therapy of filarial infection and immunological studies of malaria in a mouse model. His research team detected the essential function of Wolbachia endosymbionts in filarial nematodes and developed a therapy with doxycycline, which depletes the Wolbachia and kills the adult worms, rendering doxycycline the first safe macrofilaricidal drug against onchocerciasis. His group have performed many randomised, registered trials on onchocerciasis and lymphatic filariasis in countries including Ghana, Cameroon, Tanzania, India and Indonesia. He is the recipient of several awards and prizes, including the German Society for Hygiene and Tropical Medicine Award, and has published more than 170 papers.



Session Speakers

Dr Michael Makanga

EDCTP

Dr Makanga is a medical doctor with Masters and PhD in Clinical Pharmacology and Therapeutics. He has considerable international experience in conducting and management of health research programmes with emphasis on the conduct of clinical trials, as well as ethics and clinical regulatory affairs. As EDCTP Director of South-South Cooperation and Head of Africa Office, he is responsible for liaison with the African political leadership, policy makers and the scientific community with the purpose of ensuring a genuine African ownership, commitment and stewardship of the partnership

Professor Joseph Ndung'u

Foundation for Innovative New Diagnostics (FIND)

Professor Ndung'u is a corresponding Fellow of the Royal Society of Edinburgh, and has a PhD in Immunopathology of African trypanosomiasis. He served as the Director of the Kenya Trypanosomiasis Research Institute (KETRI) from 1995 to 2005. His area of specialisation is in sleeping sickness epidemiology and control. His programme at FIND supports the development of diagnostic tests for sleeping sickness, leishmaniasis, Chagas disease, and other NIDs.

Dr Odile Leroy

European Vaccine Initiative (EVI)

Trained as a physician, epidemiology, clinical pharmacology and vaccinology, Dr Odile Leroy has spent most of her career in vaccine development, including working as a scientist in Africa for nine years and as corporate clinical director of airborne vaccines for 10 years at Sanofi Pasteur. She joined the European Malaria Vaccine Initiative (EMVI) in 2002 as a clinical and regulatory director and held the post of Executive Director of the European And Developing Countries Clinical Trials Partnership from 2005 -2006. In 2006, Dr Leroy took up the post of Executive Director of the European Vaccine Initiative, formerly EMVI, which was created in 1998 through a supportive action of the European Commission. The European Vaccine Initiative is leading European efforts to develop effective, accessible, and affordable vaccines against diseases of poverty.

Dr Nathalie Strub Wourgaft

Drugs for Neglected Diseases Initiative (DNDi)

Dr Strub Wourgaft joined DNDi as Clinical Development Director in February 2009 and is currently Medical Director since 2010. Prior to her appointment at DNDi, Dr Strub Wourgaft was Director of Clinical Development at Trophos. She has over 15 years of clinical development experience, including with Pfizer from 2000 to 2003, and Lundbeck from 1995 to 1999. She also served as Medical Director for a CRO from 2004 to 2005 as well as for the French office of Aspreva from 2005 to 2008. Dr Strub Wourgaft graduated as Medical Doctor from Necker Hospital, Université René Descartes in Paris in 1983.



Partnerships and Collaborations Panel Members

Dr Ole Olesen

European Commission

Dr Olesen is principal scientific officer for Global Health Research at the European Commission's Directorate-General for Research & Innovation. He completed his studies in molecular biology at the universities of Aarhus, Denmark and Cambridge, UK, and subsequently also received a degree in international economics from Copenhagen Business School. Prior to taking up his current position in 2002, he worked as assistant professor in pharmacology at Copenhagen University, and for 10 years in the pharmaceutical industry in positions of increasing responsibility; most lately as global project director at Ferring Pharmaceuticals A/S.

Dr Jutta Reinhard-Rupp

Merck Serono

Dr Reinhard-Rupp is Head of Access to Health R&D & Partnerships at Merck Serono. Her focus is the development and implementation of the R&D Access to Health strategy, including the strategy for schistosomiasis. Dr Reinhard-Rupp received her PhD at the Max-Planck Institute in Tübingen. After her postdoctoral training at Novartis, she was lab head at Evotec Biosystems in Hamburg. In 1997, she joined Aventis in various assignments in Research and Development. Under her leadership, a gene therapy project was moving into clinical phase III worldwide. Since January 2008, she works with Merck Serono in Switzerland with main responsibilities on the implementation of key strategic initiatives in drug discovery and development, including the lead of the internal IMI office (European public-private partnerships) and the lead of several "access to health" programs.

Mrs Martina Gliber

Fondation Mérieux

Mrs Gliber works as international partnership manager for a French family foundation, Fondation Mérieux, which is devoted to fighting infectious diseases in developing countries by local capacity building. Her experience covers a wide range of activities: from international project coordination and management, to fundraising, networking, advocacy and lobbying activities. Mrs Gliber represents Fondation Mérieux in the global health groups of the European Foundation Centre, such as the HIV/AIDS Funders Group and the European Foundation Initiative on African Research into Neglected Tropical Diseases. Prior to this she worked at the Faculty of Medicine in Lyon and the Association of Schools of Public Health in Europe (ASPHER). She holds a Master degree in Public Health and Health Economics.

Dr Christian Loucq

International Vaccine Institute (IVI)

Dr Loucq, Director-General of IVI, is an international expert on the evaluation of vaccines in developing countries. Dr Loucq has been involved in most stages of vaccine development throughout his career from managing vaccine businesses in China, India and Thailand to working with large vaccine companies such as GlaxoSmithKline and Sanofi Pasteur, and biotechnology companies such as Rhein Biotech and Acambis. Before joining IVI, he was the Director of the Malaria Vaccine Initiative at PATH. Due to his extensive experience of working in both the private and public sectors, Dr Loucq has built dynamic collaborations to foster vaccine development that include partnering with local governments, developing public-private partnerships, and establishing local private collaborations.



Dr Morven Roberts

UK Medical Research Council (MRC UK)

Dr Roberts is the Programme Manager for Global Health Infections and Global Health Trials at the UK Medical Research Council. For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century.

Dr John Reeder

The Special Programme for Research and Training in Tropical Diseases (TDR)

Dr John Reeder is Director of TDR, the Special Programme for Research and Training in Tropical Diseases since February, 2012. He has deep experience leading international research organizations, most recently as Director of the Centre for Population Health and Head of the Office of International Health Research at the Burnet Institute, Melbourne, Australia's largest infectious disease research institute. In Melbourne, he also held a National Health and Medical Research Council (Australia) Principal Research Fellowship and a professorship at Monash University.